Kader Thiam
CSO & Senior Vice President GenOway
Seminars
Wednesday 28th October 2026
BRGSF-HIS: A Translational Model for B Cell-Targeting TCEs in Autoimmunity
2:00 pm
- Robust human lymphoid and myeloid reconstitution without GvHD, enabling long-term immunotherapy studies.
- Clinically relevant B-cell depletion and T-cell pharmacodynamics with therapies targeting autoreactive B cells.
- Integrated efficacy and CRS-like safety assessment in a single translational platform.
